The first 2 years of recombinant growth hormone therapy offers significant benefits for prepubertal children with Silver–Russell syndrome, French researchers have found.
Plasma and urine analyses are both reliable screening tests for the diagnosis of phaeochromocytoma/paraganglioma in children and adolescents, report researchers in Clinical Endocrinology.
An artificial intelligence-assisted tool can speed up anthropometric calculations for paediatric endocrinologists monitoring growth in children with achondroplasia, research indicates.
Genetic testing has identified a likely cause for nonfamilial tall stature in 11% of children examined, show study findings published in the European Journal of Pediatrics.
Research from the Netherlands suggests that the majority of children heterozygous for pathogenic alterations to the NPR2 gene, resulting in mild skeletal dysplasia, respond to growth hormone therapy.
The European Society for Paediatric Endocrinology (ESPE) has released a position statement to encourage further research into endocrine immune-related adverse events associated with the use of immune checkpoint inhibitors in children with cancer.
For teenage boys with idiopathic short stature (ISS), combining a third-generation aromatase inhibitor with recombinant human growth hormone therapy can significantly improve adult height, suggest study findings published in the Journal of Clinical Endocrinology & Metabolism.
We are excited to welcome you to the Insights into MAnaging Growth for Endocrine nurses (IMAGE) June 2025 Meeting, organised by Springer Healthcare IME. This event will take place on 5–6 June 2025 in the vibrant city of Lisbon in Portugal.
Once daily oral treatment with infigratinib has a tolerable side effect profile and a significant positive benefit on both annualised height velocity and upper-to-lower body segment ratio in children with achondroplasia, indicates research published in The New England Journal of Medicine.
Researchers have identified novel pathogenic variants that may account for approximately 9% of children with Silver–Russell syndrome who have not previously had a molecular diagnosis and aid understanding of the relationships between genotype and phenotype.
